Kolexia
Dartigeas Caroline Hématologie
Dartigeas Caroline
Hématologie
Centre hospitalier de Tours
Tours, France
150 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Lymphomes Lymphome à cellules du manteau Maladie résiduelle Leucémie myéloïde Macroglobulinémie de Waldenström Lymphome B diffus à grandes cellules

Collaborateurs

Voir plus
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Leblond Véronique
Leblond Véronique
Hôpital Pitie Salpetriere, Paris, France
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Tournilhac Olivier
Tournilhac Olivier
Hôpital Estaing, Clermont-Ferrand, France

Industries

Voir plus
B3TSI
172 collaboration(s)
Dernière en 2023
A+A
172 collaboration(s)
Dernière en 2023
Janssen
25 collaboration(s)
Dernière en 2023
Abbvie
16 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN-CLL-314: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Lenalidomide Consolidation Improves Measurable Residual Disease (MRD) Rates and Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
65th ASH Annual Meeting Abstracts   02 novembre 2023
THEMIS: Targeted Therapies in Chronic Lymphocytic Leukemia and Medico-economic Evaluation of the Ambulatory Medical Assistance Nurse Program : a Prospective Multicenter Randomized Study
Essai Clinique (CHU Toulouse)   18 septembre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
EClinicalMedicine   10 août 2023